Novel neuroprotective tripeptides and dipeptides

Annals of the New York Academy of Sciences

Volumn 1053, Issue , 2005, Pages 472-481

  Faden, Alan I ^a   Knoblach, Susan M ^a   Movsesyan, Vilen A ^a   Lea IV, Paul M ^a   Cernak, Ibolja ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CNS injury; Dipeptides; Neuroprotection; TRH analogues; Tripeptides

Indexed keywords

AZETIRELIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDE; METHYLPREDNISOLONE; MONTIRELIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; OPIATE ANTAGONIST; OROTIRELIN; PIPERAZINEDIONE; PROTIRELIN; PROTIRELIN DERIVATIVE; PROTIRELIN[3 (3,3 DIMETHYLPROLINAMIDE)]; PYRO 2 AMINOADIPYLHISTIDYLTHIAZOLIDINE 4 CARBOXAMIDE; SEROTONIN ANTAGONIST; TRIPEPTIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; BINDING AFFINITY; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HEAD INJURY; HUMAN; HUNTINGTON CHOREA; MOUSE; NERVOUS SYSTEM INJURY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PEPTIDE SYNTHESIS; RAT; SPINAL CORD INJURY;

ANIMALIA;

EID: 29744444639     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1344.041     Document Type: Conference Paper

References (39)

1. YAKOVLEV, A.G. & A.I. FADEN. 2004. Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRX 1: 5-16.
2. ENRIQUEZ, P. & R. BULLOCK. 2004. Molecular and cellular mechanisms in the pathophysiology of severe head injury. Curr. Pharm. Des. 10: 2131-2143.
3. POVLISHOCK, J.T. & D.I. KATZ. 2005. Update of neuropathology and neurological recovery after traumatic brain injury. J. Head Trauma Rehabil. 20: 76-94.
4. FADEN, A.I. 2002. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr. Opin. Neurol. 15: 707-712.
5. VINK, R. & C. VAN DEN HEUVEL. 2004. Recent advances in the development of multifactorial therapies for the treatment of traumatic brain injury. Expert Opin. Invest. Drugs 13: 1263-1274.
6. FADEN, A.I. 2001. Neuroprotection and traumatic brain injury: the search continues. Arch. Neurol. 58: 1553-1555.
7. ROYO, N.C. et al. 2003. Pharmacology of traumatic brain injury. Curr. Opin. Pharmacol. 3: 27-32.
8. CASTAGNOLA, E. et al. 2004. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant. Clin. Microbiol. Infect. 10: 255-257.
9. CIRONE, P. et al. 2004. Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells. Hum. Gene Ther. 15: 945-959.
10. MAAS, A.I. 2001. Neuroprotective agents in traumatic brain injury. Expert Opin. Invest. Drugs 10: 753-767.
11. FADEN, A.I., T.P. JACOBS & J.W. HOLADAY. 1981. Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. N. Engl. J. Med. 305: 1063-1067.
12. FEUERSTEIN, G. et al. 1983. Leukotriene D4-induced hypotension is reversed by thyrotropin-releasing hormone. Prostaglandins 26: 711-724.
13. FEUERSTEIN, G. et al. 1984. Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone. Circ. Shock 13: 2552-2560.
14. FADEN, A.I. et al. 1990. Effects of TRH-analog treatment on tissue cations, phospholipids, and energy metabolism after spinal cord injury. J. Pharmacol. Exp. Ther. 255: 608-614.
15. FADEN, A.I. 1988. Role of thyrotropin-releasing hormone and opiate receptor antagonists in limiting central nervous system injury. Adv. Neurol. 47: 531-546.
16. FADEN, A.I., R. VINK & T.K. MCINTOSH. 1989. Thyrotropin-releasing hormone and central nervous system trauma. Ann. N.Y. Acad. Sci. 553: 380-384.
17. FADEN, A.I. 1989. TRH analog YM-14673 improves outcome following traumatic brain and spinal cord injury in rats: dose-response studies. Brain Res. 480: 228-235.
18. FADEN, A.I. et al. 1999. Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents. Am. J. Physiol. 277: R1196-R1204.
19. + and water content in experimental spinal injury. Res. Exp. Med. 193: 297-304.
20. BEHRMANN, D.L., J.C. BRESNAHAN & M.S. BEATTIE. 1994. Modeling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone, U-74006F, and YM-14673. Exp. Neurol. 126: 61-75.
21. FADEN, A.I. et al. 1983. Comparison of thyrotropin-releasing hormone (TRH), naloxone, and dexamethasone treatments in experimental spinal injury. Neurology 33: 673-678.
22. BEHRMANN, D.L., J.C. BRESNAHAN & M.S. BEATTIE. 1993. A comparison of YM-14673, U-50488H, and nalmefene after spinal cord injury in the rat. Exp. Neurol. 119: 258-267.
23. PUNIAK, M.A. et al. 1991. Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma. J. Neurotrauma 8: 193-203.
24. CEYLAN, S. et al. 1990. Medical treatment of acute spinal cord injuries. Res. Exp. Med. 190: 111-119.
25. FADEN, A.I. 1993. Comparison of single and combination drug treatment strategies in experimental brain trauma. J. Neurotrauma 10: 91-100.
26. CEYLAN, S. et al. 1992. Treatment of acute spinal cord injuries: comparison of thyrotropin-releasing hormone and nimodipine. Res. Exp. Med. 192: 23-33.
27. PITTS, L.H. et al. 1995. Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J. Neurotrauma 12: 235-243.
28. PRASAD, C. 1988. Cyclo(His-Pro): its distribution, origin, and function in the human. Neurosci. Biobehav. Rev. 12: 19-22.
29. PRASAD, C. 1995. Bioactive cyclic dipeptides. Peptides 16: 151-164.
30. FADEN, A.I. et al. 2003. Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo. J. Cereb. Blood Flow Metab. 23: 3423-3454.
31. FADEN, A.I. et al. 2004. Novel small peptides with neuroprotective and nootropic properties. J. Alzheimer's Dis. 6: S93-S97.
32. REDDING, T.W. & A.V. SCHALLY. 1969. Studies on the inactivation of thyrotropin-releasing hormone (TRH). Proc. Soc. Exp. Biol. Med. 131: 415-420.
33. PROKAI, L. et al. 2004. Centrally acting and metabolically stable thyrotropin-releasing hormone analogues by replacement of histidine with substituted pyridinium. J. Med. Chem. 47: 6025-6033.
34. BRUNETTI, L. et al. 2002. Synthesis and biological evaluation of a novel pyroglutamyl-modified TRH analogue. Farmaco 57: 479-486.
35. 2. Bioorg. Med. Chem. Lett. 13: 1011-1014.
36. 13C-NMR spectroscopy of a novel, sterically constrained analogue of thyrotropin-releasing hormone. Biopolymers 29: 407-422.
37. SZIRTES, T. et al. 1986. Synthesis of thyrotropin-releasing hormone analogues. 2. Tripeptides structurally greatly differing from TRH with high central nervous system activity. J. Med. Chem. 29: 1654-1658.
38. FADEN, A.I., V.M. LABROO & L.A. COHEN. 1993. Imidazole-substituted analogues of TRH limit behavioral deficits after experimental brain trauma. J. Neurotrauma 10: 101-108.
39. FADEN, A.I. et al. 2003. Neuroprotective and nootropic actions of a novel cyclized dipeptide after controlled cortical impact injury in mice. J. Cereb. Blood Flow Metab. 23: 355-363.